A Daily Pill Helped Keep Weight Off After Weekly Injections Ended

CATEGORY: DIET & WEIGHT

Adults who traded their weekly weight-loss injection for a once-daily pill held on to most of what they’d lost: roughly 75% to 79% of their prior weight reduction was still intact a year after the switch, compared with 38% to 49% among those switched to a placebo tablet.¹ The pill was orforglipron, a GLP-1 medicine (a drug that mimics a gut hormone which curbs appetite) that comes as a tablet rather than a shot, and that US regulators approved for weight management earlier this year.

What happens after the injections is the question

Plenty of trials show the injectable drugs work. The harder question, and the one people actually live with, is what happens next, since stopping entirely tends to undo the work. When adults with obesity stopped tirzepatide in an earlier trial, they regained about half their lost weight within a year.² Cost, supply and needle fatigue push many people off the injections anyway. So this trial, called ATTAIN-MAINTAIN, asked whether a daily tablet could hold the line.

From 72 weeks of shots to a tablet or a placebo

The 376 participants came out of a head-to-head trial of the two leading injectables, where they had spent 72 weeks losing weight on either tirzepatide or semaglutide. Each person was then switched, double-blind and at random, to daily orforglipron or to a matching placebo for 52 more weeks. Neither patients nor doctors knew who got the real pill. Among tirzepatide veterans, those on the pill kept 74.7% of their weight reduction versus 49.2% on placebo. Among semaglutide veterans, the pill preserved 79.3% versus 37.6%. Waist size, blood pressure, blood sugar and cholesterol improvements largely held as well. Side effects were mostly stomach upset, mild or moderate. That’s familiar territory for this drug class. Eli Lilly, which makes both orforglipron and tirzepatide, funded and ran the study.

The bigger the loss, the harder it held

People coming off tirzepatide regained more on the pill (about 5 kg, or 11 pounds) than people coming off semaglutide (about 1 kg). The authors offer two explanations. Tirzepatide acts on two hormone pathways while orforglipron acts on one, so the handoff is a step down in firepower. And a very large weight loss, like tirzepatide’s roughly 20%, may simply be biologically harder to defend. What the trial can’t say is what happens past one year, or how the pill compares with simply staying on the injections, which no arm of this study did.

Key Takeaways

• Adults switched from weekly tirzepatide or semaglutide injections to daily oral orforglipron kept about three-quarters or more of their lost weight over the following year.
• Those switched to placebo kept only 38% to 49%, echoing earlier evidence that stopping these medicines entirely brings much of the weight back.
• Regain was larger after tirzepatide, the stronger two-pathway drug, than after semaglutide.
• The pill’s maker funded the trial, which lasted one year; longer-term maintenance is still untested.

References

1. Aronne LJ, Horn DB, le Roux CW, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature Medicine. 2026;32(7):2679–2687. link
2. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. link